Skip to main content

Coronavirus: Medical Treatments

Question for Department of Health and Social Care

UIN 18859, tabled on 15 June 2022

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the rollout of covid-19 antivirals; and what comparative assessment his Department has made of his Department's rollout of covid-19 antivirals with other comparator countries.

Answered on

24 June 2022

We are continuing to monitor the deployment of COVID-19 antivirals. In the week commencing 6 June 2022, approximately 1,600 non-hospitalised patients in the United Kingdom have received these treatments, with the total number of patients treated at approximately 63,000.

The UK Health Security Agency is also monitoring the effectiveness of the COVID-19 therapeutics nirmatrelvir+ritonavir (Paxlovid), molnupiravir and remdesivir. Both molnupiravir and Paxlovid are being trialled as part of the PANORAMIC national study. Results from the molnupiravir section of the PANORAMIC national study are expected later this summer. The Antivirals and Therapeutics Taskforce is engaging with other nations on the use, deployment and evaluation of COVID-19 therapeutics and antivirals, which will inform our approach.

Interests declared
The Member has declared that they have interests which may be relevant to the subject matter of this question.